Literature DB >> 9798947

Evidence for the existence of imidazoline-specific binding sites in synaptosomal plasma membranes of the bovine brainstem.

F M Heemskerk1, M Dontenwill, H Greney, C Vonthron, P Bousquet.   

Abstract

Nonadrenergic imidazoline-specific binding sites were characterized pharmacologically in crude cerebral membrane preparations, but little is known about their subcellular localization in neurons. As in the brainstem these sites are involved in cardiovascular regulation and peripherally imidazolines modulate neurotransmitter release, we tried to determine a possible (pre)synaptic localization in brainstem. We found a specific enrichment in (entire) synaptosome, purified synaptosomal plasma membrane (37 fmol/mg), and mitochondrial (83 fmol/mg) fractions as compared with other membrane fractions (3-8 fmol/mg). Synaptosomes appeared to be free of postsynaptic structures, and purified synaptosomal plasma membranes were devoid of mitochondrial material, as determined by electron microscopy and by comparison with the distribution of marker enzymes such as monoamine oxidase. These results show for the first time that these extramitochondrial imidazoline-specific sites are neuronal and are located on presynaptic terminals. We found high affinities for unlabeled p-iodoclonidine (subnanomolar), clonidine (0.2 nM), and efaroxan (11 nM), but idazoxan did not compete significantly for the p-[125I]iodoclonidine binding in these membranes. Therefore, these sites can be classified as I1 imidazoline receptors. In summary, we describe for the first time that high-affinity I1 receptors of the bovine brainstem are located on (pre)synaptic membranes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9798947     DOI: 10.1046/j.1471-4159.1998.71052193.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  5 in total

Review 1.  Drugs acting on imidazoline receptors: a review of their pharmacology, their use in blood pressure control and their potential interest in cardioprotection.

Authors:  P Bousquet; J Feldman
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

2.  Agmatine, an endogenous ligand at imidazoline binding sites, does not antagonize the clonidine-mediated blood pressure reaction.

Authors:  Walter Raasch; Ulrich Schäfer; Fatimunnisa Qadri; Peter Dominiak
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

3.  LNP 906, the first high-affinity photoaffinity ligand selective for I1 imidazoline receptors.

Authors:  Dragan Urosevic; Urosevic Dragan; Stephan Schann; Schann Stephan; Jean-Daniel Ehrhardt; Ehrhardt Jean-Daniel; Pascal Bousquet; Bousquet Pascal; Hugues Greney; Greney Hugues
Journal:  Br J Pharmacol       Date:  2004-06       Impact factor: 8.739

4.  Generation and characterization of novel human IRAS monoclonal antibodies.

Authors:  Bo Wang; Ying Liu; Yajun Shan; Zhenyu Yao; Xiaolan Liu; Ruibin Su; Qihong Sun; Yuwen Cong; Jin Li
Journal:  J Biomed Biotechnol       Date:  2009-08-10

5.  Identification of an imidazoline binding protein: creatine kinase and an imidazoline-2 binding site.

Authors:  Atsuko Kimura; Robin J Tyacke; James J Robinson; Stephen M Husbands; Michael C W Minchin; David J Nutt; Alan L Hudson
Journal:  Brain Res       Date:  2009-05-03       Impact factor: 3.252

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.